It has been proposed that in ductal pancreatic cancer cells the production of certain growth factors, particularly epidermal growth factor (EGF), transforming growth factor-a (TGF-a) and insulin-like growth factor 1 (IGF-1), together with the overexpression of their receptors, leads to unregulated cellular proliferation (Korc et al., 1986; Smith et al., 1987; Chen et al., 1990; Ohmura et al., 1990; Barton et al., 1991; Lemoine et al., 1992) . These growth factors bind to specific membrane receptors whose intracellular domains possess intrinsic protein tyrosine kinase (PTK) activity which is activated after ligand binding and is essential for signal transduction and biological activity. Interference with this pathway may provide a means of designing effective therapy for pancreatic cancer.
The tyrphostins are a recently described family of low molecular weight protein tyrosine kinase inhibitors Levitzki, 1990) . The characteristic active pharmacophore of these compounds is the hydroxy-cis-benzylidenemalono-nitrile moiety (Gazit et al., 1991) . These compounds have been demonstrated to be competitive inhibitors of EGF, insulin and platelet derived growth factor (PDGF) receptor kinases (Lyall et al., 1989; Bryckaert et al., 1992) and the protein kinases p6Osrc, p2Iobcr-abl, p1 85bcr-abl, pl40'b' (Anafi et al., 1992) . In addition, tyrphostins have been shown to be effective blockers of EGF and PDGF-dependent proliferation in various cells (Yaish et al., 1988; Bilder et al., 1991) . Some of these agents exhibit selectivity and can discriminate between, for example, the EGF and insulin receptors or the PDGF and EGF receptors (Yaish et al., 1988; Bryckaert et al., 1992) . More remarkably some tyrphostins can discriminate between the EGF receptor and the closely related product of the erbB-2/neu oncogene, structures that are 80% homologous in the kinase domain (Gazit et al., 1991) . It is considered that this selectivity occurs because the tyrphostins compete for the substrate site of the kinase, rather than the ATP binding site, and therefore, since different PTKs possess different substrate sites it is possible to design selective PTK inhibitors for each PTK (Levitzki, 1990; . The tyrphostins have been tested against a number of serine/threonine kinases and have been found to be inactive Yaish et al., 1988) .
Because of the importance of tyrosine kinases in the growth factor induced control of pancreatic cancer cell growth, our aim was to examine the effect of the tyrphostins T23, T47 and AG17 on the proliferation of three human ductal pancreatic cancer cell lines. On finding that AG17 was the most potent inhibitor of proliferation, we sought evidence that this effect was indeed mediated via the inhibition of PTK activity by studying phosphotyrosine levels within the MiaPaCa-2 cell line using an immunoblotting technique.
Materials and methods
Protein tyrosine kinase inhibitors Tyrphostin AG17 (RG50872) was a generous gift from Professor A. Levitzki (Gillespie et al., 1992) . Varying concentrations of AG17 (ranging from 10-5 M to 10-7 M), tyrphostin T23 or tyrphostin T47 (both ranging from 10-4 M to 10-6 M) were added to these cultures. The cells were incubated for 48 h at 37°C. DNA synthesis was assessed for the final 8 h by adding 0.5 tLCi 3H-thymidine/ well. The cells were then collected onto filter mats using a semi-automatic harvester (Inotech, Switzerland). Scintillation fluid was added to individual filter discs and the cell associated radioactivity counted in a beta counter (Packard 1900CA Tricarb (Figures 1 and 2 ). The moderately differentiated CAV cell line was only made available to us at a later date but once again it can be seen from Figure 3 Inhibition of EGF and serum-stimulated pancreatic cancer cell growth by AG17 The effect of AG17 on EGF and serum-stimulated cell growth was assessed directly by counting cell number on days 2, 3 and 6 for EGF-stimulated cells and on days 1, 2 and 3 for serum-stimulated cells since the cells grow more Figure 6 demonstrates that the growthinhibitory effect of the tyrphostin on the MiaPaCa-2 cell line was reversible following replacement of AG17-containing medium with fresh medium.
Inhibition of EGF-induced tyrosine phosphorylation by AG17 in the MiaPaCa-2 cell line It has previously been shown that tyrphostins are potent inhibitors of tyrosine kinase activity in a variety of nonpancreatic cells in vitro (Lyall et al., 1989; Bryckaert et al., 1992; Reddy et al., 1992) . To confirm that tyrphostin AG17 can inhibit tyrosine phosphorylation in pancreatic cancer cells, we examined the effect of AG17 on EGF-stimulated MiaPaCa-2 cells, which contain relatively high numbers of EGF receptors (Korc et al., 1986) . After a 15 min exposure of these cells to EGF, immunoblotting analysis using an anti-phosphotyrosine antibody demonstrated a dramatic increase in tyrosine phosphorylation of multiple proteins. AG17 inhibited this phosphorylation, notably of a 170kD band which corresponds to the molecular weight of the EGF receptor ( Figure 7) . The dose dependent effect of AG17 on this phosphorylation appeared to be similar with that seen on proliferation.
Discussion
Several reports have demonstrated that in ductal pancreatic cancer cells tyrosine kinase activity is elevated and is considered to be related to the autocrine production of certain growth factors and the overexpression of their receptors which possess intrinsic tyrosine kinase activity (Korc et al., 1986; Smith et al., 1987; Ohmura et al., 1990; Barton et al., 1991; Lemoine et al., 1992) . This knowledge provides an opportunity to target a specific component of the autocrine loop in pancreatic cancer cells with a view to therapeutic manipulation. In this paper, although all three tyrphostins inhibited pancreatic cancer cell replication, we have shown that AG17 was the most potent inhibitor of EGF and serumstimulated DNA synthesis and growth in pancreatic cancer cells by a mechanism that appears largely dependent on the inhibition of protein tyrosine kinases. In keeping with other published data using different analogues, the effects of these agents seemed principally cytostatic and reversible when the drug was removed from the culture medium. The effect of tyrphostin AG17 (RG50872) on platelet derived growth factor (PDGF) and EGF-induced DNA synthesis in rabbit vascular smooth muscle cells has been previously examined and AG17 was found to be more specific for PDGF than for an equieffective dose of EGF (IC50 PDGF 0.04 ELM, EGF 0.22 lIM) (Bilder et al., 1991) . It is unlikely that our pancreatic cancer cell lines express receptors for PDGF since Beauchamp et al. (1990) have shown that PDGF had no effect on the growth of MiaPaCa-2 and Panc-1 in vitro. However in our pancreatic cancer DNA synthesis studies we have found AG17 to be 10-100 times .0 E C 0 Day more potent than the commercially available tyrphostins T23 and T47. It was for this reason that all further work was conducted using AG17 only.
AG17 is a much less effective inhibitor of serum-induced DNA synthesis and cell growth compared with EGF-stimulated proliferation (Figures 3-5 ). This weaker inhibition of serum-dependent growth was expected since not only is EGF present in low concentrations in serum but also several other, mostly unidentified, growth factors in serum possibly stimulate growth through other tyrosine kinase receptors and/or other pathways not involving tyrosine kinases.
Since tyrphostin AG17 had such a dramatic effect on EGF-stimulated pancreatic cancer cell growth we also investigated the effect of AG17 on tyrosine phosphorylation in one of the cell lines. As predicted, when cells were pretreated with AG17 and then stimulated with EGF the phosphotyrosine level of multiple proteins was reduced. One particular protein was markedly affected by AG17 and since the molecular weight is approximately 170 kD we propose this to be the EGF receptor. However we are currently re-blotting our samples with anti-EGF receptor antibody to test this. Another important observation from the immunoblotting analysis is that the concentrations of AG17 needed to inhibit tyrosine phosphorylation were similar to those required for inhibition of EGF-stimulated DNA synthesis and cell growth.
Our data show that the tyrosine kinase inhibitor AG17 can inhibit the growth of pancreatic cancer cells. Recently several tyrosine kinase inhibitors have been shown to inhibit in vivo growth, in nude mice, of a human squamous cell carcinoma. Moreover, the combination of tyrphostins with suboptimal doses of monoclonal antibodies to the EGF receptor have been found to potentiate one another in inhibiting the growth of such tumours (Yoneda et al., 1991) . Regarding toxicity, preliminary data from this group suggest that tyrphostin-treated animals actually increased their appetite and weight during the 4 weeks of tyrphostin treatment, suggesting that these agents may not be particularly toxic. Clearly, however, pharmacokinetic and detailed toxicology studies are now required. Taking this into account, the present data raise the possibility that tyrphostins may prove to be useful new agents for the treatment of pancreatic cancer and other tumours in which there is increased tyrosine kinase activity.
